MacrophOx was launched in late 2018 by Professor Len Seymour, Dr Philip Jakeman and Dr Kerry Fisher out of the University of Oxford’s Department of Oncology. The Founders share a vision that their innovative technologies can lead to a sea-change in the ability of gene-modified cell therapies to treat common epithelial cancers that currently account for over 70% of cancer deaths.
MacrophOx is pioneering sophisticated genetic, immunological and cell biological solutions to the major challenges that currently limit cell therapy for cancer, and is aiming to lead the next generation of cell therapy products for cancer therapy.
The company is currently headquartered in the Magdalen Centre on the Oxford Science Park. This site houses some of the most exciting start-ups in medical science.